Apnimed (NASDAQ:APMD) Stock Rating Upgraded by Zacks Research

Apnimed (NASDAQ:APMD) was upgraded by Zacks Research to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Other analysts have also issued research reports about the company. Lifesci Capital began coverage on Apnimed in a report on Tuesday. They set an “outperform” rating and a $50.00 target price on the stock. Cantor Fitzgerald started coverage on Apnimed in a research note on Tuesday. They set an “overweight” rating and a $60.00 price objective on the stock. Evercore started coverage on Apnimed in a report on Tuesday. They issued an “outperform” rating for the company. Wall Street Zen raised shares of Apnimed to a “hold” rating in a research note on Saturday, August 8th. Finally, Bank of America started coverage on shares of Apnimed in a report on Tuesday. They set a “buy” rating and a $41.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $50.33.

Apnimed Stock Performance

Shares of NASDAQ:APMD opened at $28.72 on Wednesday. Apnimed has a one year low of $16.12 and a one year high of $35.29.

Insider Buying and Selling at Apnimed

In other Apnimed news, major shareholder Morningside Venture Investment purchased 312,500 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the purchase, the insider owned 7,152,713 shares in the company, valued at approximately $114,443,408. The trade was a 4.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Apnimed Company Profile

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.